Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
Relationships and Activities. The Council of Experts was supported by AstraZeneca.
Na minha lista:
| Principais autores: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Russo |
| Publicado em: |
«FIRMA «SILICEA» LLC
2020-06-01
|
| Colecção: | Российский кардиологический журнал |
| Assuntos: | |
| Acesso em linha: | https://russjcardiol.elpub.ru/jour/article/view/3919 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|